Literature DB >> 11458118

Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs.

F L Coe1, C Clark, J H Parks, J R Asplin.   

Abstract

PURPOSE: We report a new kind of assay system for urine cystine supersaturation that is accurate in the presence of cystine binding thiol drugs. We measured the molar ratio of cystine dissolved per mole of drug.
MATERIALS AND METHODS: Measured amounts of cystine crystals were incubated in buffer or urine for 48 hours with stirring. The solid phase remaining was pelleted by centrifugation, extracted into a high pH buffer and measured. D-penicillamine, tiopronin and captopril were added to determine their effect on solid phase dissolution.
RESULTS: Total cystine calculated from urine and solid measurements closely matched the amounts of cystine weighed in, meaning that the assay system successfully recovered the total cystine from the 2 phases. Each drug dissolved solid cystine in a specific and fixed proportion to its molar concentration in the range of 0.2 to 0.4 mM. dissolution per mM. of drug. Solution measurements were not a reliable gauge to the actual amounts of cystine dissolved.
CONCLUSIONS: Changes in solid phase cystine accurately reflect buffer or urine supersaturation when thiol drugs are present. The solid phase assay is a technically straightforward and reliable way of assessing cystine movement into and out of urine that avoids complexity of measurement and distortions of assay systems by drugs. This assay enables one to assess the level of drug effect and the need for a change in dosing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458118

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Cystinuria: mechanisms and management.

Authors:  Donna J Claes; Elizabeth Jackson
Journal:  Pediatr Nephrol       Date:  2012-01-27       Impact factor: 3.714

Review 2.  Kidney stone disease.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

3.  Stones: Predicting stone episodes using cystine capacity.

Authors:  Matthew Bultitude; Kay Thomas
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

4.  Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement.

Authors:  Brian H Eisner; David S Goldfarb; Michelle A Baum; Craig B Langman; Gary C Curhan; Glenn M Preminger; John C Lieske; Gyan Pareek; Kay Thomas; Anna L Zisman; Dimitri Papagiannopoulos; Roger L Sur
Journal:  J Endourol       Date:  2020-04-06       Impact factor: 2.942

5.  Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.

Authors:  Deepa A Malieckal; Frank Modersitzki; Kristin Mara; Felicity T Enders; John R Asplin; David S Goldfarb
Journal:  Urolithiasis       Date:  2019-04-13       Impact factor: 3.436

6.  Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children.

Authors:  Ralph J DeBerardinis; Curtis R Coughlin; Paige Kaplan
Journal:  J Urol       Date:  2008-10-31       Impact factor: 7.450

Review 7.  How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Authors:  Kim Hovgaard Andreassen; Katja Venborg Pedersen; Susanne Sloth Osther; Helene Ulrik Jung; Søren Kissow Lildal; Palle Joern Sloth Osther
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

8.  Cystine crystal volume determination: a useful tool in the management of cystinuric patients.

Authors:  Michel Daudon; Fabrice Cohen-Solal; Frédéric Barbey; Marie-France Gagnadoux; Bertrand Knebelmann; Paul Jungers
Journal:  Urol Res       Date:  2003-05-14

Review 9.  Update on cystinuria.

Authors:  Nicola Sumorok; David S Goldfarb
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-07       Impact factor: 2.894

Review 10.  Cystinuria-a urologist's perspective.

Authors:  Kay Thomas; Kathie Wong; John Withington; Matthew Bultitude; Angela Doherty
Journal:  Nat Rev Urol       Date:  2014-03-25       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.